new glp-1 drugs Guidelines for Type 2 Diabetes in 2025 Eli Lilly to seek approval
Description
These medications are not indicated for type 1 diabetes
Weight and body composition: Record baseline weight, BMI, and waist circumference
Doustdar thinks the program could be an opportunity to regain some of the ground Novo's Wegovy shot has lost to Lilly's Zepbound
December 2025: Ascletis Pharma announced that ASC30, an oral small-molecule GLP-1 receptor agonist, demonstrated 7.7% placebo-adjusted weight loss in a 13-week U.S
i , Quantification of cFOS + cells in rostral linear nucleus raphe (RR)
